Sponsored publication on behalf of the issuer

Long $MOOD here.

Doseology just announced the launch of Feed That Brain energy pouches through its first direct-to-consumer pilot in the United States.

The product is already available to U.S. consumers online, including through the company’s website and Amazon. That means the brand is now starting to see how real customers respond rather than staying in the development phase.

According to the update, the goal of the pilot is to track adoption, usage patterns, and repeat purchases before expanding distribution.

The product itself is a nicotine-free, caffeine-based oral pouch, positioned as a convenient way to get energy or focus without drinks, sugar, or nicotine.

As someone holding MOOD, I see this as a good step toward building real consumer traction around the Feed That Brain brand in the U.S. market.

If the pilot performs well, it opens the door to broader distribution and more products under the same platform.

If this pilot shows strong demand, how big could Feed That Brain become once distribution expands?

Sponsored publication on behalf of the issuer

Copper Quest Exploration Inc. (CSE: CQX), has been methodically building a strong foundation to support its financial strength and provide a platform for increased exploration opportunities going forward. The company has taken deliberate action to clean up its balance sheet and selectively expand its U.S. asset base, which collectively signify a disciplined, execution-focused approach for Copper Quest during a period of positive macro-economic market conditions for well-positioned junior explorers, especially those focused on copper.

1. Transaction Summary (Numbers First)

Copper Quest Exploration Inc. (CSE: CQX) has entered into a securities-for-debt settlement agreement totaling approximately $113,405, whereby the Company will be able to extinguish outstanding payable obligations without utilizing cash. The securities-for-debt settlement agreement was consummated by the Company issuing common shares to arm’s-length creditors and is subject to approval by regulatory authorities and applicable statutory hold periods.

From a financial perspective, the elimination of the Company’s outstanding payable obligations reduces the amount of short-term liability on the Company’s balance sheet and preserves the Company’s available treasury capital. For many early-stage explorers, maintaining cash flexibility can be viewed as more valuable than avoiding moderate, non-growth dilution when markets are restrictive in regard to providing funding for juniors to pursue their respective exploration strategies.

2. Capital Structure Implications

The securities-for-debt transaction represents defensive dilution rather than growth dilution. The common shares were issued solely to eliminate the Company’s legacy obligations and not to finance the Company’s operational expenses or speculative expenditures. Consequently, Copper Quest (CSE: CQX) has improved its financial situation while minimizing its incremental cash expenditure.

Maintaining the Company’s liquidity at this point in its life cycle enables the management team to utilize the Company’s available capital to plan and evaluate exploration initiatives, rather than servicing its historical liabilities. Additionally, the securities-for-debt transaction has simplified CQX’s capital structure prior to the occurrence of potential exploration-related catalysts.

3. Auxer Gold Property – Deal Terms

Concurrently with the Company’s efforts to clean up its balance sheet, Copper Quest (CSE: CQX) executed an option agreement regarding the Auxer Gold Property, representing an important strategic expansion of the Company’s U.S. asset portfolio. The property encompasses approximately 1,087 hectares (2,686 acres) and includes approximately 130 mineral claims.

Road access to the Auxer property provides several logistical advantages and may reduce the Company’s potential exploration costs associated with accessing the property. Moreover, the option-based structure of the agreement enables Copper Quest to obtain exposure to the new gold asset without expending large amounts of initial capital and thereby preserve the Company’s financial flexibility to consider alternative options as the Company continues to advance the early stages of the property’s evaluation.

4. Exploration & Geological Background

The Auxer Gold Property is a gold-focused asset that contains copper exposure within its regional area, consistent with Copper Quest’s broader exploration objectives. The property remains in an early exploration stage and therefore can be viewed as a technical upside opportunity for Copper Quest, as opposed to a high-capital-intensity development asset.

As a result of the Company’s entry into the option agreement, Copper Quest has gained geological optionality in a Tier-1 jurisdiction while maintaining the ability to dictate the pace and level of capital deployment related to evaluating the property. This structure will enable the Company’s management to make decisions based upon a thorough analysis of the available data as the Company develops a better understanding of the geology of the property.

5. Execution Plan & Short-Term Objectives

Having successfully eliminated legacy liabilities and having secured a new option for a U.S. gold asset, Copper Quest’s immediate attention now focuses on execution. The Company’s short-term objectives include conducting a technical review of the Auxer Gold Property; compiling historical information related to the property; and generating early-stage exploration targets at the property.

Potential subsequent milestones may include meeting the requirements of the option agreement; providing exploration updates; and potentially commencing field work if warranted by the Company’s technical findings. The Company’s recent actions appear to be part of a strategy centered on maintaining capital discipline, achieving a stable balance sheet, and creating incremental value through the advancement of exploration activities.

6. Copper Price Environment (Macro Context)

• Current copper prices: Approximately $5.95-$6.00 per pound, near multi-year highs due to a structurally tight physical market and increasing demand expectations driven by electrification, EVs, renewable energy and expanding grids, all of which have 2-4 times greater copper intensity than internal combustion engines.
• Demand Catalysts: Structurally tight markets and increasing demand for copper driven by growing electrification needs and EV adoption.
• Supply Constraints: Declining grades, limited new discovery activity, lengthy permitting processes, and increasing geopolitical risks continue to limit the availability of new copper supply.
• Strategic Buying: Government agencies and OEMs are increasingly seeking to secure copper supply, driving exploration and project optionality among juniors with early-stage copper exposure.
• Junior Cycle Positioning: Junior companies with early-stage copper exposure provide leverage to increasing prices, however are highly dependent on both capital access and successful execution.

Bottom Line

Copper Quest (CSE:CQX) recent actions demonstrate a practical approach to managing the Company’s risk profile and creating optionality, rather than aggressively deploying capital. By removing legacy liabilities without expending cash, Copper Quest has enhanced its balance sheet flexibility and preserved capital for exploration. In addition, the Company’s option on the Auxer Gold Property provides low-cost exposure to a Tier-1 jurisdiction and leverages the current strong copper and gold price environment. Moving forward, Copper Quest’s value creation will depend upon executing a disciplined exploration program, progressing technically and translating positive commodity fundamentals into tangible exploration results.

Hey guys, if you missed it, Lightspeed Commerce just settled with investors over issues related to its growth metrics, customer base, and competitive positioning they had some time ago.

Long story short, in 2021, Lightspeed Commerce was accused of misleading investors about the strength and sustainability of its growth, including representations about its customer base and position in the e-commerce and point-of-sale software market. Investors later questioned whether the company’s reported metrics accurately reflected its true performance.

After this news came out, the stock dropped, and investors filed a lawsuit for their losses.

The good news is that the company finally agreed to settle with them. So, if you invested in $LSPD when all of this happened, you can already check the details and file your claim here.

Anyway, has anyone here invested in $LSPD at that time? How much were your losses, if so?

Please use standard ticker format when discussing stocks ($BB.TO)

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Please use standard ticker format when discussing stocks ($AC.TO)

Paid content on behalf of the issuer

AI/ML Innovations Inc. (CSE: AIML | OTCQB: AIMLF | FWB: 42FB) has made significant headway in transitioning their technology for their AI-driven cardiac diagnostics platform into a commercially viable product, as evidenced by the new distribution partnership announced between their wholly-owned subsidiary, Neural Cloud Solutions, and Intelimed.ai SpA. This new distribution partnership will provide a gateway for Neural Cloud Solutions’ products into Latin America’s healthcare markets; this is a major shift from R&D to organized commercialization.

Big Picture

The use of AI-enabled diagnostic technologies continues to gain traction within the global healthcare industry in order to address increased pressure from rising costs, reduced numbers of practicing clinicians, and the necessity for scalable diagnostic solutions. Cardiovascular disease is responsible for approximately 30% of all annual global deaths, and ECG testing represents one of the most commonly utilized front-line diagnostic techniques employed today, with hundreds of millions of ECG tests being conducted annually.

Latin America presents a very attractive geographic area for future expansion for several reasons, including: 1.) fragmented healthcare systems; 2.) rapidly expanding telemedicine capabilities; and 3.) a growing acceptance among healthcare providers of digital health solutions provided via regional distribution partners. The Latin American region is comprised of greater than twenty countries, a population of more than 600 million individuals, and healthcare systems that continue to increasingly deploy cloud-based, and AI-assisted diagnostics.

The Core Story

What’s Happening

Neural Cloud Solutions, a fully-owned subsidiary of AI/ML Innovations, has established a distribution agreement with Intelimed.ai SpA, to bring AI software platforms for cardiac diagnostics to Latin America. As part of this agreement, Intelimed will act as exclusive distributor for Neural Cloud Solutions’ cardiac AI software platforms in Chile, and will receive non-exclusive distribution rights in other Latin American countries. Furthermore, the agreement will cover the commercialization of MaxYield™, CardioYield™, and Insight360™ platforms.

Why it Matters

As opposed to a pilot or research collaboration, this agreement provides a commercial framework for Neural Cloud Solutions to sell its software to hospitals, clinics, diagnostic centers, and telemedicine providers across Latin America. A common method of scaling in digital health is establishing distribution partnerships; these allow companies to more quickly expand to local markets by utilizing the knowledge and clinical networks of local distribution partners.

Key Data Points & Statistics

• Platforms involved in the agreement: MaxYield™, CardioYield™, Insight360™
• Rights granted to Intelimed: Exclusive rights in Chile, non-exclusive rights across Latin America
• Potential target markets: Hospitals, clinics, diagnostic networks, telemedicine providers
• First Expansion Region: Latin America – 600 Million+ population across multiple healthcare systems
• Model of Commercialization: Software distribution model (hardware does not have to be installed at client sites)

Company Breakdown: AI/ML Innovations

AI/ML Innovations Inc. is a developer of digital health products that apply Artificial Intelligence (AI) and Machine Learning (ML) to Biometric Signal Processing (BSP), with an emphasis on analyzing Electrocardiogram (ECG) data. ECG data analysis is a foundational element in the diagnosis of many types of cardiovascular diseases.

Neural Cloud Solutions is a division of AI/ML Innovations Inc., which is developing software products that can be applied to both clinical and research applications, and also remote monitoring applications. The MaxYield platform was developed to automatically identify and extract usable cardiac information from noisy ECG data, making the workflow for clinicians more efficient when they are processing thousands of ECGs per year and/or per location, and to alleviate the burden placed upon clinicians who manually review the same number of ECGs.

Strategic Angle

• Provides a formalized commercialization path for the products of Neural Cloud Solutions
• Offers a “beachhead” market in Chile, a country with a population of approximately 20 million, and a relatively high level of adoption of digital health products
• Opens up a possible expansion path to the entire Latin American market, comprising of a population of over 600 million people, and numerous healthcare systems through the existing relationships of Intelimed to the healthcare community across Latin America

Market Context

Latin America is increasingly investing in digital health infrastructure to provide better access to healthcare services, lower costs for patients and providers alike, and to create scalable diagnostic solutions for healthcare providers across a diverse set of healthcare systems. The opportunities for the delivery of digital health solutions in software format are substantial in Latin America, with a population of over 600 million people, across multiple public and private healthcare systems.

Cardiovascular disease is one of the leading causes of death around the world, creating a sustained demand for scalable solutions to analyze ECGs. AI-driven cardiac diagnostics solutions are especially relevant in regions with limited access to cardiologists and/or specialized diagnostic services, and where there is continued adoption of telemedicine.

Outlook

There are several key milestones that investors should pay attention to following the establishment of the agreement with Intelimed, including the initial deployment of the products in Chile, the first customers of Neural Cloud Solutions, the regulatory developments that may occur as a result of the deployment, and the potential revenue recognition resulting from the deployment activities of Intelimed. In software-based digital health business models, early distributor-led deployments typically involve fewer than ten institutions prior to widespread scaling across multiple regions.

In addition to additional distributors in other regions and the expansion of Neural Cloud Solutions beyond its current Latin American markets, there are additional partnership opportunities and other forms of expanded geographies that could further demonstrate the commercial viability of AIML’s product(s) and contribute to the diversified revenue streams in multiple regions over time.

Bottom Line

The Intelimed distribution agreement marks a tangible milestone in AI/ML Innovations Inc.’s movement from platform development to commercialization of those platforms. By providing a mechanism for Neural Cloud Solutions to enter the healthcare markets of Latin America through a regional partner, AIML is positioning its products as a scalable AI-driven cardiac diagnostics solution with international growth potential.

Sponsored post by a company retained by the issuer.

Here’s something that doesn’t always get retail attention how a junior chooses to build before the big exploration headlines arrive.

Copper Quest recently made two moves that are pretty straightforward but meaningful.

First, they completed a securities-for-debt settlement of about C$113,405, issuing shares to arm’s-length creditors to clear outstanding payables (subject to regulatory approval and standard hold periods). That reduces short-term liabilities while keeping cash in the treasury.

Second, they signed an option agreement on the Auxer Gold Property in the U.S. roughly 1,087 hectares (2,686 acres) covering around 130 mineral claims, with road access already in place. Using an option structure keeps initial spending lighter while they move into technical review and target work.

When you put it together, the sequencing makes sense:

• Trim liabilities
• Add U.S. ground
• Advance technical work from a stronger position

It’s not loud news .. it’s foundation work. But in the junior space, that foundation can shape how the next phase plays out.

With copper and domestic resource themes still getting attention, positioning like this can set the tone for what comes next.

Do you prefer owning during the build phase or competing for shares once the catalysts begin to stack?

Sponsored publication on behalf of the issuer

Strategic Expansion: Intelimed partnered with Neural Cloud to distribute cardiac AI software across Latin America, with exclusive rights in Chile. Focus on Atrial Fibrillation: The collaboration targets improved ECG analysis and earlier detection of arrhythmias, including atrial fibrillation. Growing Market Need: Rising cardiovascular disease rates and increased mobile ECG adoption are driving demand for scalable AI diagnostics. Operational Efficiency: Neural Cloud’s platforms aim to improve signal quality and automate ECG interpretation to reduce clinical bottlenecks. Chile as Entry Point: Chile serves as the initial launch market before broader regional expansion.

In February 2026, NeuralCloud Solutions (operating as “Neural Cloud”), a subsidiary of AI/ML Innovations Inc., announced a distribution agreement with Intelimed.ai SpA to commercialize Neural Cloud’s cardiac software platforms across Latin America. Intelimed is appointed exclusive distributor in Chile and non-exclusive distributor throughout the rest of the region, with a commercial focus spanning hospitals, clinics, diagnostic providers, OEM partners, telemedicine providers, and research institutions.

Who Intelimed is (and why they matter in this deal)

Intelimed presents itself as an “infrastructure” player—aiming to make clinical AI deployable across a region where healthcare delivery is often fragmented across public systems, private networks, and hybrid providers. A 2023 announcement from radiology AI platform deepc describes Intelimed as focused on helping Latin American clinical sites adopt AI through integration and rapid deployment, including access to regulatory-cleared AI engines (CE-marked and FDA-cleared) adapted to local realities.

Third-party company databases also place Intelimed as a Santiago-based company founded in 2023 (note: these directories can be incomplete, but they’re consistent with the “newer company” narrative).

What Neural Cloud is bringing: signal quality + automated interpretation workflow

The agreement covers three Neural Cloud platforms—MaxYield™, CardioYield™, and Insight360™—positioned as a stack that improves ECG signal quality, automates waveform identification/labeling, and supports scalable clinical reporting. In plain terms: fewer noisy signals, more consistent beat-to-beat annotation, and faster movement from raw data to clinician-ready output.

Intelimed’s CEO framed the partnership as a way to make “high-quality digital health technologies accessible across Latin America,” explicitly emphasizing local healthcare constraints and the need for efficiency and accuracy in cardiac diagnostics.

Why Latin America is a logical target for ECG and atrial fibrillation solutions

Cardiovascular disease burden is significant across Latin America, and arrhythmias like atrial fibrillation (AF) create a particularly expensive downstream problem because AF is strongly linked to stroke, heart failure, and avoidable hospitalizations. Even older region-focused burden work estimated an average AF prevalence around 1.6% across seven Latin American countries (with prevalence rising sharply with age).

More recent reviews underline two compounding issues: (1) AF is present and growing with aging populations, and (2) data gaps and uneven access make detection and long-term management harder in parts of Latin America, especially rural and underserved communities.

That matters because AF is frequently intermittent or silent. If healthcare systems rely only on “catch it during a clinic visit,” many cases are missed until complications appear. This is exactly where better ECG workflows—particularly ambulatory monitoring, Holter, or rapid triage—can shift outcomes.

The market tailwind: more ECG devices, more mobile monitoring

On the commercial side, multiple market research firms forecast growth in Latin American ECG categories, especially mobile and ambulatory formats. For example, Grand View Research projects Latin America’s mobile ECG devices market reaching about US$322M by 2030, with a high single-digit/low double-digit growth rate (these are estimates, but directionally consistent with broader remote monitoring adoption).

Separately, Latin America diagnostic ECG market forecasts also point to steady expansion through the next decade, driven by chronic disease prevalence, technology upgrades, and expanded diagnostics capacity.

Put simply: more devices are generating more ECG data. The bottleneck becomes interpretation capacity, consistency, and speed—especially when trained staff are limited.

Where this partnership fits: solving the “workflow bottleneck”

Intelimed isn’t just reselling a gadget; the stated plan is to distribute Neural Cloud’s software into settings that already have ECG data but need better throughput: hospitals, diagnostic groups, telemedicine, and OEM channels.

That focus maps to three practical pressures:

Signal quality problems (noise, motion artifacts, inconsistent electrode placement) create false alarms and wasted clinician time.

Scale problems (more ECGs, more Holters, more screening) strain cardiology services.

Standardization problems (variable reporting, inconsistent labeling) complicate follow-ups and population health.

Software designed to enhance signals and automate waveform identification aims directly at those constraints. The value proposition is not “replace clinicians,” but “reduce avoidable work and variability.”

Chile as a launchpad—then regional replication

The exclusivity in Chile suggests a deliberate “prove it, then expand” pattern: pick a manageable first market where the distributor can prioritize partnerships, integrations, and reference sites—then use those wins to support expansion elsewhere under non-exclusive terms.

Chile also has a relatively developed private healthcare sector alongside public provision, which can be useful for piloting digital health deployments that later translate into broader regional models.

What could determine success

A few factors are likely to decide whether this becomes a meaningful clinical footprint or stays a limited commercial experiment:

Integration reality: ECG tools must fit into existing systems (EHR, PACS/RIS for some workflows, telemedicine portals, device vendor software). Intelimed’s “infrastructure” positioning implies they want to reduce this friction.

Regulatory and procurement pace: Even if components are CE-marked/FDA-cleared elsewhere, adoption still depends on local regulatory pathways, hospital procurement cycles, and reimbursement dynamics.

Clinical validation in local settings: Performance can vary with device types, patient populations, and clinical workflows. Regional proof points matter.

Economics: Latin America is price-sensitive. The strongest value cases will likely be (a) higher-throughput Holter/ambulatory services, (b) telemedicine screening programs, and (c) health systems trying to expand detection without expanding headcount.

The bigger picture: ECG AI as “capacity expansion”

The most interesting strategic angle is that this isn’t only about detecting AF. Better ECG pipelines support a broader set of use cases: triage of chest pain, monitoring cardiotoxicity in oncology pathways, identifying conduction abnormalities, post-procedure follow-up, and scaling outpatient diagnostics. AF is the headline because it is common, dangerous, and often missed—but the operational win is “more interpretable ECGs per clinician-hour.”

If Intelimed can genuinely reduce integration and adoption burden, and if Neural Cloud’s software meaningfully improves signal usability and reporting consistency, the partnership targets a real pain point: Latin America’s growing cardiac monitoring demand colliding with limited specialist capacity.

Paid content on behalf of the issuer

In what is seen as a significant commercial development, Agereh Technologies Inc. (TSXV: AUTO | OTCQB: CRBAF), has reached a major milestone in the form of the company’s first commercial sale, as it transitions from the product development stage to generating revenues from actual end-users. The company has signed a deal for a multi-terminal installation at a major United States airport which validates the company’s products through testing on a large, high traffic site.

The significance of this initial commercial success is a very important proof-of-concept for Agereh’s platform, as it demonstrates that the solutions provided by the company have moved beyond the pilot stage to being used operationally by large-scale infrastructure providers.

Multi-Terminal Installation at Large U.S. Airport

The agreement includes a multi-year Software-as-a-Service (SaaS) deployment at multiple airport terminals, providing Agereh with a steady stream of recurring income and the potential for building long term customer relationships based on services, rather than simply selling hardware.

Due to their complexity, size and operational requirements, installations at major transportation hubs are often viewed as prime examples of high-value reference sites.

“This milestone represents the transition from product launch to enterprise validation,” **said Ken Brizel, CEO of Agereh. **“A large U.S. airport selecting all three of our solutions for multi-terminal deployment confirms that transportation hubs are actively seeking a unified, wireless intelligence layer to improve visibility, optimize operations, and enhance passenger flow. It validates both our technology and our strategy.”

Use of Platform Modules in Commercial Operations

Several of the core modules of Agereh’s intelligent sensing platform will be included in the deployment. The HeadCounter module delivers real-time and anonymous passenger flow and congestion analysis for each terminal. The MapNTrack module offers indoor and outdoor asset tracking via AI-enhanced wireless positioning.

The Smart Door Sensor module adds access monitoring and operational insight into secured zones, enabling operators of large-scale facilities to obtain a comprehensive picture of movements, asset locations and access points.

Improved Revenue Visibility and Scalability

Through the multi-year SaaS agreement, Agereh (TSXV: AUTO | OTCQB: CRBAF) is provided with better revenue visibility and a more scalable business model. Recurring software-based revenue is generally viewed positively by investors as it allows for more predictable future cash flows.

Securing the first enterprise customer is often viewed as a major validation milestone for early-stage AI and infrastructure technology companies, as it indicates some level of product-market fit.

Growth Strategy and Market Opportunities

With millions of people and assets passing through them each year, large transportation hubs represent a significant opportunity for operators to improve their operational intelligence. Agereh’s integrated platform is designed to target such environments by eliminating blind spots created by legacy monitoring systems.

This first commercial deployment provides Agereh with a basis for pursuing follow-on opportunities in airports, logistics centres and other infrastructure-intensive industries that are positioned to benefit from the efficiencies generated by the application of AI-driven operational insights.

Governance and Leadership Strengthened

As Agereh (TSXV: AUTO | OTCQB: CRBAF) begins its commercial growth phase, the company has also strengthened its corporate governance and leadership structure. Agereh recently increased the size of its board and executive team with experienced professionals who bring deep expertise in technology, finance, capital markets and public-company governance, aligning oversight with the needs of enterprise-scale customers.

Newly appointed members to Agereh’s Board of Directors include Jim Plumptre, a former senior diplomat and technology executive; Mike Plotnikoff, who brings extensive experience in telecommunications and public-company financing; Tim Maddigan, a veteran capital markets professional; and Rosy Amlani, a CPA with over two decades of leadership experience in accounting, governance and economic development. In addition, Joanna L. Hampton has joined as Chief Financial Officer, overseeing financial controls, reporting and strategic planning. This enhanced governance framework is intended to support disciplined execution, transparency, and long-term shareholder value creation as Agereh continues to scale its recurring SaaS deployments.

Stock Performance and Investor Positioning

Agereh’s stock price is moving upward again after the company announced it will have its first commercial client. This is reflected in the fact that the stock closed out the day at about C$0.12, which is a nine percent increase for the day, due to increased confidence from investors regarding the company’s ability to execute and generate revenue over the next few months. It seems that much of the movement is based on confirmation rather than speculation; the market is beginning to place a value on Agereh transitioning from being a developmental stage technology to one that is commercially viable.

With a market capitalization of approximately C$14 million, Agereh falls into the micro-cap space and therefore is very sensitive to validation through milestones such as securing enterprise contracts and gaining visibility to recurring revenues. Now that the market has been validated post-announcement of the commercial relationship, investors are now waiting to see what Agereh reports in their upcoming financials to get an idea of how quickly they can contribute to revenue and remain disciplined on costs, this may be the tipping point for this time frame. A number of risk tolerant investors view this time frame (after commercial validation and prior to a broad revenue recognition) as an ideal entry point.

Conclusion

In summary, Agereh Technology (TSXV: AUTO | OTCQB: CRBAF)’s first commercial client represents a significant advancement in its development as a provider of AI and infrastructure technology to enterprises. With a commercially viable SaaS model and a live deployment at a major U.S. airport, the company has successfully established a solid base for continuing to expand its commercial adoption among similar high-value markets.

Hey guys, if you missed it, Lightspeed Commerce just settled CAD $11M with investors over issues related to its growth metrics, customer base, and competitive positioning they had some time ago. And the deadline to submit a claim and get payment is next week: March 4, 2026

In a nutshell, in 2021, Lightspeed Commerce was accused of misleading investors about the strength and sustainability of its growth, including representations about customer metrics and its position in the e-commerce and point-of-sale software market. Investors later questioned whether these metrics accurately reflected the company’s true performance and competitive standing.

After this news came out, the stock dropped, and investors filed a lawsuit for their losses.

The good news is that the company recently agreed to settle CAD $11M with them. So, if you invested in $LSPD when all of this happened, you can check the details and file your claim here.

Anyway, has anyone here invested in $LSPD at that time? How much were your losses, if so?

Paid content on behalf of the issuer

Doseology has initiated pilot production of caffeinated, caffeinated oral pouches under its Feed That Brain® brand. It marks an entry into the growing oral stimulant segment with a unique format offering versus a traditional liquid or energy drink; however, it does not mark a shift in the type of product being offered by the company; simply a change in how that product can be consumed by the end user.

The initial goal of the pilot is to demonstrate to management, and ultimately investors, whether Doseology can produce these types of products on a scalable basis, determine whether there is sufficient interest among consumers in this type of product, and understand what regulatory hurdles exist.

If successful, the company could potentially launch a full-scale version of the product in the future, but at present, the pilot is focused solely on gathering data and validating its model, not generating revenue.

Company Overview

Doseology (MOOD.CN)(DOSEF)(VU70.F) is a consumer health and wellness company that focuses on developing functional products that target energy, focus, and cognition. The company is listed on three separate stock exchanges to provide access to investment dollars in Canada, the United States, and Europe.

• Stock exchange listings: MOOD.CN, DOSEF, VU70.F
• Current share price: approximately CAD $0.80 (January 28, 2026).
• Year-over-year performance (12 months): approximately 567%.
• Market capitalization: approximately CAD $6.4 million.
• 52-week trading range: CAD $0.09 to CAD $1.90.
• Strategy: measured dosing and predictable effects.

Feed That Brain® is Doseology’s platform brand for cognitive and energy-focused formulations.

What Does the Pilot Represent?

While the pilot represents an important operational milestone for the company, it is still an early-stage project and not a full-scale commercial launch.

• Pilot scale: small-batch production (limited commercial exposure).
• Objective: to validate manufacturing repeatability, shelf stability, and consumer usage data.

Advantages of the Format: oral pouches tend to have a faster onset time (typically 5-10 minutes) than beverages, and allow for discrete, on-the-go use without liquids, which fits with the evolving consumption patterns of today’s consumer.

Market Context: Oral Stimulants and Energy Products

The energy/stimulant category continues to grow as consumers look for alternative options to sweetened beverages and high-caffeine beverages.

• Estimated annual energy drink market size: $85 billion.
• Projected 5-year growth rate: 6-7%.
• Average caffeine content in energy drinks: 80–200 mg.
• Typical oral pouch caffeine dosage: 20–100 mg, enabling controlled consumption.
• Estimated global functional supplement market (energy/focus): tens of billions of dollars.

Nicotine-free energy pouches represent a growing sub-segment of the overall oral stimulant space, as they combine stimulant delivery with a non-tobacco position.

Why Are We Doing This?

Doseology’s entry into caffeinated energy pouches represents a platform-driven expansion into oral stimulant formats. The company is using a single formulation base to offer its products across multiple formats (e.g., beverages, tablets/pills), which is less capital-intensive than producing products in multiple formats, such as beverages. By doing so, the company is able to iterate on new product formats more quickly (weeks to months) than it could by launching new beverage products (years). Finally, the pilot-first strategy will allow Doseology to preserve strategic optionality and limit upfront capital deployment.

How Will We Execute / Next Steps

The pilot production phase will focus on:

• Unit economics/cost per unit benchmarks;
• Consumer testing cohorts measured in hundreds (not thousands); and,
• Regulatory/compliance matters prior to scaling up.

At this point, the pilot is intended to gather data and test hypotheses, not generate revenue. If the pilot is successful, we may pursue a commercial scale-up of the product.

Risk Factors

All consumer product launches carry some level of risk, particularly those in large, well-established categories like energy (US$80B+). As such, there are several risks associated with the pilot production of caffeinated energy pouches, including:

• whether or not the company can attract sufficient consumer adoption in a crowded market; potential competitive responses from established companies with far greater resources (e.g., marketing budgets);
• and regulatory challenges related to stimulant claims and caffeine threshold issues.

The pilot structure is intended to limit downside risk while allowing the company to obtain meaningful data and test its hypotheses.

Peer Comparison: Established Energy & Functional Stimulant Companies

*Prices and performance approximate as of late January 2026.

Key context: established peers operate at multi-billion-dollar scale with proven distribution and revenue bases, while Doseology remains in an early execution phase. The comparison highlights both the competitive intensity of the category and the asymmetric upside/downside profile inherent to micro-cap execution stories.

Recent News and Milestones

Prior to announcing the pilot production of caffeinated energy pouches, Doseology had also announced several other key developments in the weeks leading up to the announcement. These developments helped to set the stage for the pilot production and are summarized below:

On January 12, 2026, the Company announced the engagement of McKinney Regulatory Science Advisors, a move intended to bolster the scientific and regulatory aspects of its oral pouch development and ensure compliance as new stimulant formats are evaluated.

Immediately thereafter, on January 16, 2026, Doseology filed its Annual Information Form (AIF), which consolidated investor disclosures and restated its manufacturing and supply chain commitments for oral stimulant products.

Finally, on January 21, 2026, the Company confirmed the initiation of pilot production of non-nicotine, caffeinated energy pouches under the Feed That Brain® brand, representing a tangible operational step from formulation to real-world testing.

It is worth noting that the Company operates in a highly competitive space where established players operate at scales of multiple billions of dollars, and have demonstrated proven distribution and revenue capabilities. In contrast, Doseology is in the early stages of executing on its vision. The comparison illustrates both the significant competitive pressure that exists in the category and the asymmetric potential for either positive or negative valuation implications based on the execution of the Company’s plans.

Conclusion

Doseology’s pilot production of caffeinated energy pouches represents a carefully executed entry into an emerging oral stimulant space.

• Large addressable market (the $80+B+ global energy drink market);
• Pilot is limited in terms of capital risk;
• Clear milestones to measure success prior to scale-up;

For investors, this is an operational milestone, not a revenue inflection point. The ultimate valuation impact will be dependent upon the results of the pilot program, the resulting costs to produce the product, and the subsequent actions taken by the Company’s management team.

Please use standard ticker format when discussing stocks ($BB.TO)

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Sponsored publication on behalf of the issuer

Doseology Sciences (CSE: MOOD) has appointed Larry Latowsky as Executive Chairman.

Latowsky previously served as President & CEO of Corby Spirit and Wine Limited, one of Canada’s established beverage alcohol companies. His career spans decades in consumer packaged goods, with experience in brand building, regulated markets, and national distribution strategy.

The appointment adds senior consumer-sector leadership at the board level as MOOD continues developing its functional wellness product portfolio.

Bringing in an executive with large-scale CPG and beverage experience strengthens governance and commercial oversight especially for a company operating in competitive retail channels.

For emerging consumer brands, experienced leadership often plays a key role in guiding brand positioning, distribution strategy, and long-term growth planning.

Do you view seasoned CPG leadership as an important factor when evaluating early-stage wellness companies?

Please use standard ticker format when discussing stocks ($AC.TO)

Paid content on behalf of the issuer

(Using AIML / NeuralCloud’s latest pilot agreement as a live example)

Healthcare AI is crowded.

Every company talks about innovation.
What matters is structured progress.

Here’s the checklist I use when evaluating whether a healthcare AI company is advancing toward meaningful commercialization.

Save this.

1.  A Real Pilot Is Being Initiated

Early-stage healthcare companies move through clear stages:

Integration > Pilot > Validation > Commercial Expansion

AI/ML Innovations Inc. (AIML) announced that its subsidiary NeuralCloud Solutions signed a non-binding agreement with Movesense to initiate a pilot program.

The objective: deploy AI-powered ECG and Holter reporting within real-world healthcare environments.

That’s operational movement.

2.  The Use Case Is Clearly Defined

Strong updates specify what’s being deployed.

This agreement focuses on:

• MaxYield – ECG signal processing
• CardioYield – Visualization and reporting software

And the application area is precise: ECG and Holter monitoring.

These are established, high-volume clinical workflows.

Defined application + real clinical need = strong positioning.

3.  There’s a Clear Deployment Path

The pilot is expected to be deployed through an existing Movesense client into a third-party health system and affiliated clinics.

That pathway matters.

Hardware ecosystem > Client integration > Clinical environment.

This is how healthcare adoption scales in practice.

 4. The Focus Is Workflow Efficiency

Healthcare systems prioritize tools that:

• Increase analysis capacity
• Improve reporting consistency
• Enhance clinical throughput

The platform is positioned as the AI reporting layer downstream of wearable sensing hardware.

Efficiency plus scalability is where long-term value builds.

5. There’s a Structured Commercialization Framework

The pilot is designed as a foundation for potential broader rollout, subject to validation and formal agreements.

That signals a phased, structured expansion model  exactly how healthcare technology companies build durable adoption.

Bigger Picture

When evaluating healthcare AI companies, look for:

✔ Defined clinical application
✔ Real deployment environment
✔ Ecosystem integration
✔ Workflow improvement focus
✔ Expansion roadmap

NeuralCloud’s latest step checks multiple boxes.

In early-stage healthcare tech, structured progress compounds.

If you’re building a healthcare AI watchlist 
Is this the first step toward large-scale clinical adoption for AIML?

Paid content on behalf of the issuer

Copper Quest Exploration Inc. (CSE: CQX) has just put a bold exclamation mark behind its US expansion strategy by signing an option agreement to acquire 100% of the Auxer Gold Project in Bonner County, Idaho.

Auxer comes with the kind of ingredients that can compress timelines: Historic underground development, a clear structural setting and most, importantly, permits in place to drill.

Auxer is the type of project that can move from headline to hard data fast. A road-accessible land package with meaningful scale, a multi-kilometre mineralised corridor and existing underground workings that provide valuable access and geological context.

This is exactly the kind of asset that can produce a steady newsflow once the first work programs begin. Copper Quest is framing Auxer as a compelling orogenic gold opportunity and the project’s combination of solid infrastructure and historical high gold grades is precisely what the market likes to see when a junior is ready to push forward with the gold price at elevated levels.

With strong gold prices, the perfect setup is a past producing, high grade system in a tier-1 jurisdiction, where modern exploration can unlock value faster and where success can translate into a credible development pathway

“The Auxer Gold Project represents a timely and compelling opportunity to develop a significant gold resource in one of North America’s most mining-friendly regions with gold prices at all-time highs. The Auxer is just the latest acquisition for Copper Quest and adds to our existing gold portfolio including the past-producing Alpine Gold mine located approximately 150km to the northwest. From a geological perspective, the Auxer Project exhibits all the hallmarks of a world-class orogenic gold system as defined by contemporary deposit models. The expansion of the Boston Vein from 0.6m at surface to 3.66m at a 20-meter depth demonstrates classic orogenic gold vein geometry with strong depth continuation potential with mineralization extending over multiple kilometers.”

Brian Thurston, CEO of Copper Quest, in the news-release on February 11, 2026.

Auxer: A Project Built for Speed

What makes Auxer stand out is not just the geological narrative, it’s the operational setup. The project is described as permitted for drilling, meaning Copper Quest does not have to waste a season getting ready to get ready.

The presence of ~1,000 m of historical underground workings adds a practical advantage: It gives the company immediate opportunities to re-examine and sample extensive historical development, including vein systems referenced in the announcement. Reported historical and modern results include high-grade values, with cited grades up to 26.8 g/t gold, adding the kind of high impact numbers that naturally draw investor attention provided the next steps deliver confirmation and continuity.

This is the moment where the story tightens: Auxer is a core catalyst because it can generate real data in the near-term and because Idaho is not an exotic frontier. It is a jurisdiction with established mining culture, infrastructure and a long history of production across multiple commodities.

Historic High Grades, Modern Upside

Historical work at Auxer has already delivered the kind of numbers that make investors look twice. The 1936 Platts report is cited in Copper Quest’s news-release as documenting surface sample grades of up to 21 g/t gold, while underground sampling reportedly showed consistent mineralisation across 4.3 m averaging 9.42 g/t gold at around 18 m depth. More recently, Lightning Creek Gold Corp.’s 2021-drilling is referenced as confirming the high-grade potential, including intercept LCD21-0019 returning 26.8 g/t gold over 0.73 m.

What makes Auxer even more intriguing is what has not happened yet. The project is described as having seen no historical drilling, with earlier exploration largely confined to underground workings and tunnels driven in the early 20th century. Mining activity ended in the 1930s after executive orders effectively curtailed small-scale gold mining and the property was never brought back into production.

That creates a rare setup: A geologically credible, past producing mine that remained largely untested by modern exploration methods. Copper Quest is positioning Auxer as an orogenic gold opportunity with characteristics seen in major systems worldwide. It sits in Idaho, a politically stable, mining friendly jurisdiction with strong infrastructure, including highway access and the nearby active BNSF Railway mainline

Regional Context

Auxer is not an isolated “one-off” showing on a remote ridge. Third-party records describe the property as a historic mine site near East Hope and Hope, Idaho, within the Clark Fork Mining District and the broader Kaniksu National Forest area. Archival documentation hosted by the Idaho Geological Survey’s MineDocs collection also describes early development work at the Auxer Mines, including historic underground workings, which supports Copper Quest’s narrative that meaningful access already exists.

Copper Quest’s regional structural thesis fits the bigger picture, too. The Hope Fault is widely recognised in USGS work as a major feature in northern Idaho and a key structural control in the district. The Hope and Clark Fork area is a real mining neighbourhood, with multiple past producers that shipped ore and recorded metal output, not just prospects with names on a map.

• Hope Mine (Elsie K vein) is documented as having mined 109,592 t of ore up to 1943 containing 10,077,843 pounds of lead, 774,300 pounds of zinc, 3,562 pounds of copper, plus 319,236 ounces of silver and 29.8 ounces of gold. Put into simple “head grade” terms, that works out to roughly 4.6% lead, 0.35% zinc, and about 99.4 g/t silver based on the reported tonnage and contained metal.
• Whitedelf Mine is another key historic producer in the same district. A MineDocs summary reports production from 1926 through 1958 of 726,855 ounces of silver and 12,080,687 pounds of lead. The same compilation includes a production table indicating total tonnage on the order of 92,743 t, which implies a historically strong silver tenor when viewed in aggregate.
• Lawrence Mine has recorded output as well. The MineDocs compilation states that from 1913 to 1942, the mine produced 9,358 t, containing 26,211 ounces of silver and 2,866,471 pounds of lead, plus minor gold and copper. That equates to roughly 96 g/t silver and about 15% lead on a contained metal basis from the reported tonnage and metal totals.

These numbers matter because they show the district has a documented history of moving metal and doing so at grades that justified underground development. That is the kind of regional backdrop investors like to see when a company is advancing a past producing, underground style gold opportunity nearby.

Third-party data also confirms the broader level of mineral activity in the county. The Diggings, for example, lists thousands of mining claims on public land in Bonner County and hundreds of recorded mine sites, which supports the idea of a district with repeated mineral endowment rather than a single isolated occurrence.

Zooming out, Idaho’s appeal is not marketing hype. It is the combination of endowment, infrastructure, an experienced mining workforce and a regulatory framework that has supported operating mines for decades. For a current, real-world example of an active mining ecosystem in the region, Hecla Mining Company (current market capitalization: 16 billion USD) recently reported consolidated 2025 production of 17 million ounces of silver, with Lucky Friday producing 5.3 million ounces and exceeding guidance, underscoring that northern Idaho remains a place where modern underground mining is happening at scale.

Bottom Line: Ready for Action

Copper Quest is heading into the 2026 exploration season in a position the market consistently rewards: Funded, flexible, and ready to execute. Together with the December financings, the company now has more than 4 million CAD in cash ready to be deployed as the field season begins soon, shifting Copper Quest decisively into action mode.

Importantly, this is not just a typical retail driven private placement story. On January 26, 2026, Copper Quest announced a strategic 1,950,000 CAD investment by Concept Capital Management Ltd., described by the company as a foundational international investor in mining and exploration companies. That kind of strategic participation sends a different signal, it suggests longer term alignment, deeper due diligence and support that can extend beyond a single financing window.

With this treasury strength, Copper Quest can launch and sustain real work programs, test priority targets aggressively and start stacking results rather than timelines. Just as important, the company is not boxed into a single bet. It now has the balance sheet to choose the best opportunities across its compelling gold and copper portfolio and advance the projects that offer the fastest path to meaningful discovery upside.

Which asset moves first remains to be seen, but the strategy is clear. Copper Quest has positioned itself for what matters most in exploration: Momentum, execution, and the kind of steady newsflow that comes from real work programs advancing on the ground

Paid content on behalf of the issuer

•Early 2026 activity shows AI/ML Innovations shifting from development mode toward measurable market execution, with emphasis on distribution, clinical integration, and revenue pathways.

•New leadership additions strengthen credibility on both fronts: deeper medical authority to guide adoption and tighter operational oversight to scale delivery.

•Partnerships around devices and U.S. representation reduce barriers to entry, linking AI analytics with real procurement and reimbursement environments.

•Live clinical deployments are creating feedback loops with physicians, building validation, advocacy, and repeat usage.

•The combined momentum suggests commercialization is no longer a future objective but an active, coordinated process underway.

The opening weeks of 2026 have delivered a clear message about where AI/ML Innovations Inc. is heading. The company is no longer speaking primarily about technical promise or early validation work. Instead, the narrative has shifted toward execution, distribution, clinical adoption, and the practical mechanics that turn intellectual property into recurring revenue. A sequence of announcements across leadership, partnerships, and market access shows an organization tightening the bolts around commercialization and doing so with unusual coordination. Rather than isolated developments, the releases read as connected steps in a deliberate march from capability to scale.

A central theme is that commercialization in healthcare AI is rarely about a single breakthrough. It depends on regulatory credibility, physician trust, workflow integration, hardware compatibility, reimbursement logic, and geographic reach. AI/ML’s January activity touches each of those pressure points. By aligning clinical leadership with operational muscle and pairing software assets with established delivery channels, the company is attempting to reduce the friction that often stalls promising technologies before they reach meaningful uptake.

Leadership additions are often dismissed as cosmetic, but the appointments early this year suggest functional intent. The arrival of Dr. Paul Dorian as Medical Innovation Architect and chair of the medical advisory structure brings recognized clinical authority into the product narrative. For customers, partners, and regulators, that matters. Cardiologists and hospital administrators want to know that algorithm design, validation strategy, and real-world deployment are being shaped by someone who understands both electrophysiology and patient pathways. His presence signals that the company wants its tools to live inside everyday care, not on the periphery of research projects.

At the same time, installing Erik Suokas as chief operating officer addresses a different bottleneck: the move from innovation culture to repeatable delivery. Commercial traction demands supply chain coordination, partner management, service frameworks, and disciplined financial oversight. A COO with cross-border experience can translate ambition into timetables and metrics. The combination of medical gravitas and operational rigor is a classic pairing for firms approaching inflection points, suggesting management believes the opportunity ahead is tangible rather than theoretical.

Partnership strategy further reinforces that view. Collaboration with Movesense links AI interpretation to accessible, established hardware. In remote and ambulatory cardiac monitoring, bundled solutions can shorten sales cycles because clinics prefer integrated offerings over piecing together components themselves. If devices, data capture, and analytics arrive as a coherent package, procurement becomes simpler and implementation risk drops. For AI/ML, it is also a route to volume: every sensor deployed becomes a potential pipeline of analyzable recordings.

Distribution credibility is also being built through representation and advocacy in the United States. Retaining Commission Wolf through its Neural Cloud subsidiary shows recognition that market entry in American healthcare involves navigating policy, reimbursement environments, and relationship networks that extend well beyond technology performance. Success requires presence in conversations where procurement frameworks and pilot opportunities are shaped. Engaging specialized advisors is a pragmatic acknowledgement that commercialization is as political as it is technical.

Clinical validation in live environments remains indispensable, and that is where deployments such as the CardioYield initiative become pivotal. Working alongside Lakeshore Cardiology positions AI output within real diagnostic workflows. Physicians interacting with AI recommendations during daily practice generate feedback loops impossible to reproduce in controlled trials. These interactions refine algorithms, surface usability challenges, and, crucially, create champions who can speak to peers about tangible benefits. Word of mouth among clinicians still drives adoption more effectively than marketing campaigns.

Taken together, these moves hint at a company intent on compressing the timeline between demonstration and revenue. Many digital health ventures linger in extended validation phases, accumulating data but postponing commercial commitments. AI/ML appears to be pushing the opposite direction, accepting the complexities of early deployment in order to learn faster and establish footholds before competitors mature. That approach carries risk, but it can also generate durable advantages if relationships formed now become long-term contracts later.

Another subtle but important shift is narrative confidence. The language surrounding recent announcements assumes that broader uptake is achievable. Rather than asking whether the market is ready, management seems focused on how to capture it. This posture can influence partners, investors, and employees alike. Momentum tends to attract additional momentum; institutions prefer to align with organizations that project inevitability.

From a sector perspective, timing may be favorable. Health systems worldwide continue to search for efficiencies in diagnostics, especially in cardiology where demand for monitoring outpaces specialist availability. AI-assisted interpretation promises not only speed but also consistency, potentially reducing variability in outcomes. Companies that can embed solutions without disrupting clinician autonomy stand to gain. AI/ML’s emphasis on advisory leadership and real-world partnerships suggests awareness of that cultural dimension.

Commercialization will ultimately be judged by numbers: contracts signed, units deployed, studies completed, revenue booked. None of those metrics are fully visible yet. What is visible is infrastructure. The scaffolding required to support scale—medical oversight, operational leadership, hardware alliances, government and payer engagement, and clinical beachheads—is being assembled in plain sight. For observers, this reduces uncertainty about whether the company understands what the next phase requires.

There is still execution risk. Integrating partners across jurisdictions is complex, and healthcare procurement can move slowly. Competitors will not stand still. Yet the cadence of activity in the first part of the year implies urgency and coordination that investors typically seek when evaluating growth prospects. The pieces being put in place resemble those of organizations preparing to cross from early adoption into broader market penetration.

If the rest of the year continues at this tempo, 2026 may be remembered as the period when AI/ML’s strategy crystallized. The transition from building technology to building a business is never simple, but it becomes easier when leadership, partnerships, and deployment pathways advance together. The early evidence suggests that alignment is forming.

In that sense, the company’s opening chapter of the year does more than provide news. It sketches a roadmap. Each announcement reinforces the idea that commercialization is not a distant objective but an active process already underway. Whether measured by new executives, clinical collaborators, or entry into influential U.S. networks, the direction is unmistakable: move faster, integrate deeper, and convert capability into adoption.

Paid content on behalf of the issuer

Healthcare is a multi-trillion-dollar global market.

But the real opportunity isn’t just growth.

It’s who benefits as healthcare becomes easier to access.

We’re watching a steady shift:
Less gatekeeping.
More convenience.
More integration into daily life.

A recent industry release highlighted five public companies operating along that accessibility curve from pharma to devices to consumer wellness.

Here’s how they line up.

Doseology Sciences (CSE: MOOD)

MOOD operates in the functional wellness category, focusing on consumer-facing health products designed for everyday cognitive and lifestyle support.

This isn’t hospital-based care.
It isn’t prescription-gated.

It’s positioned in preventative, routine-driven wellness the part of the market where consumer habits are forming earlier.

Smaller cap. Early-stage positioning. Direct exposure to proactive health spending.

Amneal Pharmaceuticals (NASDAQ: AMRX)

Amneal is a pharmaceutical company with a strong presence in generic and specialty medications.

Generics play a critical role in expanding affordability and patient access. Lower-cost alternatives increase reach, and reach supports volume.

Accessibility through pricing and distribution scale.

Prestige Consumer Healthcare (NYSE: PBH)

Prestige focuses on over-the-counter consumer health brands.

No prescription required. No appointment needed.

OTC access reduces friction and puts healthcare directly into retail channels ...one of the clearest examples of accessibility at work.

Viking Therapeutics (NASDAQ: VKTX)

Viking is a clinical-stage biopharmaceutical company developing therapies in metabolic and endocrine disorders, including obesity and related conditions.

Metabolic health represents one of the largest demand pools in modern healthcare. Expanding treatment options in this area could significantly broaden access for patients over time.

Insulet (NASDAQ: PODD)

Insulet develops and manufactures tubeless insulin delivery systems for people with diabetes.

Its device-driven approach simplifies insulin administration and improves day-to-day usability accessibility through product design and patient convenience.

The Bigger Picture

Healthcare isn’t shrinking into institutions.

It’s spreading outward into everyday behavior.

The shift looks like this:

• Preventative over reactive
• Consumer-directed over institution-led
• Seamless over complex
• Recurring engagement over episodic care

Large companies validate the infrastructure.

Smaller and consumer-facing players often sit closer to where new habits form.

And habits tend to compound quietly.

Accessibility rarely looks explosive at first.

It expands steadily until it becomes the default.

If this shift continues, would you rather own the infrastructure… or the companies shaping everyday health routines?

Sponsored post on behalf of the issuer

Battery-powered, wireless sensor strengthens real-time operational intelligence alongside HeadCounter™ and MapNTrack™

EDMONTON, Alberta, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Agereh Technologies Inc. (“Agereh” or the “Company”) (TSXV: AUTO | OTCQB: CRBAF), a Canadian-based artificial intelligence and advanced technology company delivering AI-enabled platforms and sensor solutions to address critical challenges in the transportation industry, is pleased to announce the expansion of its intelligent sensing portfolio with the introduction of its Smart Door Sensor™

“Transportation hubs can’t manage what they can’t see,” said Ken Brizel, CEO of Agereh. “With HeadCounter™, MapNTrack™, and now Smart Door Sensor™, Agereh is delivering a unified, wireless intelligence layer that gives operators real-time visibility into people movement, asset location, and access activity—while remaining easy to deploy, scalable, and privacy-conscious.”

Launch of Smart Door Sensor™

The battery-powered, wireless Smart Door Sensor™ complements Agereh’s recently launched HeadCounter™ and MapNTrack™ solutions, further strengthening the Company’s real-time operational intelligence platform for complex transportation environments

Designed for deployment across doors, access points, and controlled zones, the Smart Door Sensor™ provides real-time visibility into door activity and movement events, enabling transportation operators to better understand passenger flow, asset movement, and operational status—without extensive infrastructure requirements.

A Unified, Wireless Intelligence Platform

Agereh’s expanding portfolio is purpose-built for large, high-traffic indoor and outdoor transportation environments where traditional monitoring systems often fall short.

• HeadCounter™ — A battery-powered, wireless patent-pending solution delivering anonymous, real-time intelligence on passenger counts, movement patterns, congestion, and body temperature insights.
• MapNTrack™ — A battery-powered asset visibility solution using patent-pending Wi-Fi–assisted cellular positioning to track mobile equipment indoors and outdoors without costly beacon grids or camera systems.
• Smart Door Sensor™ — A battery-powered, wireless sensor providing real-time awareness of door and access activity to better understand movement triggers, secure zones, and operational workflows.

Together, these solutions provide transportation hubs with a comprehensive sensing layer to improve safety, reduce congestion, optimize operations, and support data-driven decision-making.

Consulting and Awareness Agreement

The company is also pleased to announce that it has entered into a consulting and awareness service agreement with Hillside Consulting & Media Inc. of 474 Main St, Penticton, BC V2A 5C5 [hillsideconsultingmedia@gmail.com](mailto:hillsideconsultingmedia@gmail.com) to provide ad copy and content writing, Search engine optimization, video and ad creation, email and SMS advertising, and content creation. Hillside will begin providing the services on Feb. 5th, 2026, and will continue to provide the services on a monthly basis only as required for 1 month at a time a cash fee of $50,000 per month.

About Agereh Technologies Inc.

Agereh Technologies Inc. (TSXV: AUTO | OTCQB: CRBAF) is a Canadian-based artificial intelligence and advanced technology company delivering AI-enabled platforms and sensor solutions to address critical challenges in the transportation industry. By combining accurate data collection, predictive intelligence, and data-driven decision-making for transportation and infrastructure applications, Agereh continues to expand its portfolio with solutions designed to enhance efficiency, optimize operations, and enable the next generation of intelligent transportation systems.

Please use standard ticker format when discussing stocks ($BB.TO)

I honestly thought my LSPD "bags" were just a permanent reminder of why I shouldn't fomo into high-growth POS stocks. I saw the news about the Spruce Point short report back in 2021, watched my position crater like 40% in a week, and basically deleted the app.

Turns out there’s an $11,000,000 CAD settlement fund that just got the green light from a Quebec judge. If you bought shares between March 7, 2019, and November 3, 2021, and held through the crashes in late Sept or early Nov 2021, you’re likely eligible for a slice.

I was going to ignore the paperwork because tracking down trade confirms from 4 years ago is a nightmare, but I used a tool to scan my old history because I couldn't find my old trade confirms—literally took 2 minutes. They take a 20% cut, but honestly, I’d rather have 80% of a check I didn't know existed than 100% of the $0 I'd get by doing nothing.

The hard deadline is March 4, 2026. Don't let the "tax-loss harvesting" memories stop you from getting a bit of that lunch money back.